Center of attention has moved to the newest working thing: management's energy is disproportionately on a small but alre
The model's full reasoning — Q2 2023 call → NOWe need to determine if management devotes a disproportionate share of energy, enthusiasm, and detail to one identifiable part of the business that is still a minority of overall results today, and that part is described as already producing real current business (actual revenue, orders, customers, volumes, openings, bookings, deployments happening now), with management treating it as the main driver. The transcript is about Nanobiotix, a biotech company. The call covers their clinical programs, partnership with Janssen, financials, etc. The main product is NBTXR3, a radioenhancer. They have multiple clinical trials. The company is pre-revenue? They have some revenue from research tax credit and LianBio collaboration. But the core business is developing NBTXR3. The call discusses various trials: NANORAY-312 (Phase 3 head and neck), Study 102 (Phase 1 head and neck), pancreatic cancer, non-small cell lung, esophageal, etc. They also have a partnership with Janssen for global licensing. The question: Is there a specific piece that is smaller today than the established base, yet receives richest discussion, and is described as already producing real current business? The company is a clinical-stage biotech, so no product is on the market yet. They have an approved product in Europe? Actually, they mention "Hensify in soft tissue sarcoma" - they had a positive Phase 3 and got approval in Europe. So that is an approved product, but it's not generating significant revenue? The call doesn't mention sales of Hensify. The focus is on NBTXR3 in various indications. The partnership with Janssen is a major deal, but that's a one-time event? The call discusses the partnership as a key achievement, but it's not a product line. The favored piece might be the head and neck program? Or the IO combination? But all are in development, not yet producing revenue. The question asks: "Is that favored part described as ALREADY PRODUCING real, current business (actual revenue, orders, customers, volumes, openings, bookings, or deployments happening now)?" In a biotech, that would be if they have a product on the market with sales. They have Hensify approved in Europe, but the call doesn't mention any sales or revenue from it. The call focuses on clinical trials and future data. The company's revenue is from research tax credit and collaboration, not from product sales.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| APAM | Artisan Partners Asset Management Inc. | Q3 2023 | 2023-11-01 | C+ |
| ANGO | AngioDynamics, Inc. | Q1 2024 | 2023-10-04 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| PKX | POSCO Holdings Inc. | Q3 2022 | 2022-10-24 | D |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| SLQT | SelectQuote, Inc. | Q2 2022 | 2022-02-07 | F |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
YMM · Q2 2022 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clear, extended spotlight to the commission/online transaction service (20%+ of revenue, minority share). They repeatedly highlight its strong performance, dynamic adjustments, user retention metrics, and role in driving monetization and future growth, framing it as a key driver for the company's trajectory while 347.8 million in commissions is already generating real revenue now. Other areas like overall GTV, fulfillment rates, and user MAUs receive routine coverage, but the commission piece gets the richest, most conviction-driven discussion.
PUMP · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its prepared remarks and Q&A to the FORCE electric fleet offering (a new technology/service line). They describe it as minority today (only two fleets operating out of 14-15 active, with plans for three and four more), yet repeatedly highlight its real 2023 performance (on contract, strong results, efficient performance, customer satisfaction, diesel displacement), its unique positioning, and its role as the core driver of the company's future trajectory through fleet transition and industrialization.
NICE · Q4 2023 → YESThe question is: Does management devote a clearly DISPROPORTIONATE share of its energy, enthusiasm, and detail to ONE identifiable part of the business that is still a MINORITY of the company's overal...YES The transcript shows management devoting a clearly disproportionate share of its energy, enthusiasm, and detail to AI (Enlighten AI, Copilot, Autopilot) as the catalyst driving growth across CXone, digital engagement, platformization, and new solutions. This is framed as the overarching theme that will shape the 2024 trajectory and beyond. AI is described as already producing real, current business activity: 375% increase in Enlighten bookings in Q4, multiple seven-digit ACV deals won with AI features, and accelerating adoption among customers and prospects.